Moderna and Merck's melanoma vaccine intismeran shows promise in trials, potentially opening new approaches to cancer treatment through personalised mRNA vaccines. | Science & technology
Promising study data from the pharmaceutical companies Moderna and Merck give hope to patients and investors. However, there are still hurdles for a broad application of the technology.